2022
P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
Jiang Y, Jin D, Henneges C, Penuel E, Hiew H, Paulson J, Bazeos A. P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). HemaSphere 2022, 6: 1153-1154. PMCID: PMC9429719, DOI: 10.1097/01.hs9.0000847936.41396.29.Peer-Reviewed Original Research
2019
S845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL
Paulson J, Jin D, Sokol E, Nielsen T, Venstrom J, Trabucco S. S845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL. HemaSphere 2019, 3: 377. DOI: 10.1097/01.hs9.0000561660.80605.a5.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaTumor mutational burdenComprehensive genomic profilingNeoantigen burdenImmune surveillanceClinical outcomesPrognostic insightsPoor outcomeEstimate tumor mutation burdenMedian tumor mutation burdenPersonalized cancer vaccine strategiesHigh tumor mutational burdenLarge B-cell lymphomaEvasion of immune surveillanceVaccination strategiesCancer vaccine strategiesAssociated with worsened outcomesB-cell lymphomaMultivariate Cox regressionImpact clinical outcomesCell of originMHC-I presentationBCL2 alterationsDLBCL cohortPrognostic factors